Charles River Laboratories International, Inc. (CRL)
After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy
Aldeyra Therapeutics' stock plummeted 74% due to an FDA Complete Response Letter for reproxalap but presents a favorable risk-reward for speculative investors. Despite past setbacks, ALDX's history of resilience and upcoming trial results offer potential catalysts for recovery, with minimal near-term dilution risk. ALDX's strong cash position and reduced burn rate provide a safety net, with significant upside potential if reproxalap trials succeed and FDA approval is achieved.
Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate
Charles River and Valo Health identify a potential therapeutic for lupus using their combined offering, Logica.
Charles River (CRL) Up 1.9% Since Last Earnings Report: Can It Continue?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
Deciphering Charles River (CRL) International Revenue Trends
Examine the evolution of Charles River's (CRL) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance
On Wednesday, Charles River Laboratories International Inc CRL reported fourth-quarter 2024 revenue of $1 billion, a decrease of 1.1% year over year, beating the consensus of $983.63 million.
Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript
Charles River Laboratories International, Inc. (NYSE:CRL ) Q4 2024 Earnings Call February 19, 2025 8:30 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chair, President and Chief Executive Officer Flavia Pease - Executive Vice President and Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore Matt Sykes - Goldman Sachs Tejas Savant - Morgan Stanley Dave Windley - Jefferies Ann Hynes - Mizuho Justin Bowers - Deutsche Bank Lucas Romanski - TD Cowen Michael Ryskin - Bank of America Max Smock - William Blair Jacob Johnson - Stephens Patrick Donnelly - Citi Casey Woodring - JPMorgan Operator Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories Fourth Quarter and Full Year 2024 Earnings Conference Call. This call is being recorded.
CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall
Charles River's organic revenue growth in Manufacturing Solutions is more than offset by lower revenues in the RMS and DSA segments.
Compared to Estimates, Charles River (CRL) Q4 Earnings: A Look at Key Metrics
The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Charles River Laboratories (CRL) Tops Q4 Earnings and Revenue Estimates
Charles River Laboratories (CRL) came out with quarterly earnings of $2.66 per share, beating the Zacks Consensus Estimate of $2.50 per share. This compares to earnings of $2.46 per share a year ago.
Charles River beats quarterly estimates on stable demand for drug development services
Charles River Laboratories on Wednesday beat fourth-quarter profit and revenue estimates, helped by stable demand for its drug discovery and development services from biotech clients.
Gear Up for Charles River (CRL) Q4 Earnings: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Is Now the Right Time to Hold on to Charles River Stock?
CRL's solid prospects in the DSA segment and strategic partnerships present a promising opportunity for investors.
